Phase 1 N=56 Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions
Healthy
Primary: AUC0-∞ — 3960; 3400; 3350; 3420 ng*h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=70 Relative Bioavailability of 2 Oral Formulations of Nintedanib
Healthy
Primary: AUC0-tz — 300; 310; 306 ng*h/mL — p=<0.0001
Phase 1 N=54 Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval t for Total Dabigatran. — 1220; 1160; 893 ng∙h/mL
Phase 1 N=26 Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
Tumor
Primary: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞) of Sitravatinib — 2524.7; 2892.6 h*ng/mL
Phase 1 N=12 Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
Bioavailability
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (Clast) (AUClast) of Nirmatrelvir — 35020; 31700; 35990…
Phase 1 N=18 Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
Healthy Volunteers
Primary: AUC0-tz of BI 1467335 — 3.90; 2.24; 2.49 nanomole*hour/Liter (nmol*h/L)
Phase 1 N=18 A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
Healthy
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time (AUCinf) Following Single Oral Doses of Encorafenib 75 mg Alone and With…
Phase 1 N=48 A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
Erectile Dysfunction
Primary: Area Under the Curve (AUC 0-t) — 1467.00; 1458.45; 1493.53 ng*hr/mL
Phase 1 N=36 Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride
Healthy
Primary: Cmax — 31.27; 35.50 ng/mL — p=0.0082
Phase 1 N=40 Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers
Healthy
Primary: Linagliptin: Maximum Measured Concentration (Cmax) — 5.36; 5.39 nmol/L
Phase 1 N=46 The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
Healthy
Primary: Cmax (Maximum Observed Concentration of Drug Substance in Plasma) — 564.09; 543.71 pg/mL
Phase 1 N=28 A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)
Healthy
Primary: Area Under the Steady-state Plasma Concentration-time Curve (AUClast) of SSP-004184 After One Dose — 261901.9; 164340 ng*h/mL
Phase 2 N=49 Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
Rheumatoid Arthritis (RA)
Primary: Dose-Normalized AUC[0-Inf] for MTX — 109.47; 140.84; 136.45 ng*hr/mL/mg
Phase 4 N=12 Bioavailability Study for New Atorvastatin Formulation
Hypercholesterolemia
Primary: Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48) — 135.05; 140.79 ng.h/mL
Phase 1 N=32 Relative Bioavailability and Food Effect Study of CVN424
Parkinson's Disease
Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted…
Phase 1 N=12 Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4164.32; 4057.42…
Phase 1 N=28 Relative Bioavailability of Evobrutinib Tablet Batches
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib — 198; 164; 207; 205 hour×nanogram per milliliter…
Phase 1 N=24 Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5200; 5090 nmol*h/L
Phase 1 N=35 RDEA3170 Tablet and Capsule Bioavailability Study
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) — 14.9; 23.4; 12.9; 14.0 ng/mL
Phase 1 N=38 Relative Bioavailability of Pimasertib in Cancer Patients
Neoplasms
Primary: Maximum Observed Plasma Concentration (Cmax) — 254.6; 314.1 nanogram per milliliter (ng/mL)
Phase 1 N=85 Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 107.3; 95.5; 424.5; 471.0 ng/mL
Phase 1 N=22 Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule
Healthy
Primary: Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)] — 2833; 2821 ng*hr/mL
Phase 1 N=67 Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation
Safety · Bioavailability · Pharmacokinetics
Primary: Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClast — 12341; 25001; 10016.2…
Phase 1 N=18 Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects
Healthy Adult Male
Primary: Maximum Plasma Concentration (Cmax) of OPC-34712 — 47.4; 44.9; 46.1 ng/mL
Phase 1 N=18 Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 18048; 16007; 17042 ng/mL
Phase 1 N=36 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions
Healthy
Primary: Maximum Plasma Morphine Concentration — 5.23; 4.15 ng/mL
Phase 1 N=12 Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
Bioavailability
Primary: AUCinf of Nirmatrelvir Following the Administration of Nirmatrelvir/Ritonavir in Different Delivery Vehicles Under Fasted Conditions — 28670; 30780; 33170; 36020…
Phase 1 N=36 Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions
Healthy
Primary: Maximum Plasma Morphine Concentration — 4.60; 4.29 ng/mL
Phase 1 N=34 Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2
Healthy Volunteers
Primary: Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)] — 89.04; 100.9 nmol*h/L
Phase 1 N=30 Bioavailability of Different Applications of Dabigatran in Healthy Volunteers
Healthy
Primary: AUC0-inf for Total Dabigatran — 599; 1050; 928 ng(nanogram)*h(hour)/mL(milliliter)